Search by Medical Condition
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for Neoplasms, Squamous Cell
- Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
- IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
- Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study
- Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)
- Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer
- Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.
- Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
- Anrotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
- Pembrolizumab Alone or in Combination With Ipatasertib for the Treatment of Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
- HMBD-001 in Advanced HER3 Positive Solid Tumours
- Induction Chemotherapy Combined With Toripalimab in Locoregionally-Advanced Laryngo-Hypopharyngeal Squamous Cell Cancer
- A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer
- Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
- SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer
- Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer
- First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
- Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer
- A Study of SGN-B6A in Advanced Solid Tumors
- Inhibition of Oral Tumorigenesis by Antitumor B
- Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma
- Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
- Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma )
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
- SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer
- Study of TVEC in Patients With Cutaneous Squamous Cell Cancer
- PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
- Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
- SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer
- A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer
- Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer
- Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
- Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
- Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer
- Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment
- RFA to Prevent Metachronous Squamous Neoplasia Recurrence After Complete Endoscopic Submucosal Dissection
- Impact of Ribociclib on Head and Neck Squamous Cell Cancer
- A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719
- Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma
- Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
- Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
- The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
- Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
- Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
- Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer
- A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
- Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
- Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients
- Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer
- Safety Study of SEA-CD40 in Cancer Patients
- Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
- Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer
- Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
- Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
- Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling
- Randomized Study of Beet Root in Locally Advanced Squamous Cell Cancer of the Head and Neck
- Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.
- A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
- Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer
- AF CRT +/- Nimorazole in HNSCC
- Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC
- Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer
- A Study of ABT-414 in Subjects With Solid Tumors
- Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
- Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
- Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer
- A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
- Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer
- GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
- Study of BKM120 in Advanced Squamous Cell Carcinoma of Head and Neck
- Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer
- PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma
- Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer
- A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
- Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer
- Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
- Reirradiation and Erbitux in the HNSCC
- Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
- Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
- Everolimus Versus Placebo in Head and Neck Cancer
- A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck
- Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea
- Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin
- Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial
- Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
- RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN
- Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
- CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
- Study of Sorafenib/Cetuximab in Head and Neck Cancer
- Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
- Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
- Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer
- RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus
- Zalutumumab in Non-curable Patients With SCCHN
- Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer
- Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
- Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
- Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer
- Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
- Zalutumumab in Patients With Non-curable Head and Neck Cancer
- Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer
- The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
- IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
- Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck
- OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
- A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer
- Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck